Driving a new model for point of care cellular cancer immunotherapy manufacturing

Published: 16 April 2021
John Powderly,
R. Brent Dixon,
Jennifer Montague,
Steve Bradley

John Powderly is Founder and President of Carolina BioOncology Institute (CBOI), PLLC in Huntersville, NC. Dr. Powderly attended Georgetown Medical School from 1991–95 and was awarded the Lawrence Dean Scholarship. His 4th year of Med School was spent at National Cancer Institute (NCI) as an internship on the Immunotherapy Service. From 1995–1999 he attended the University of Texas, at Houston Health Science Center for a combined Medicine/Pediatrics Residency. In 1999–2000 he was appointed faculty at MD Anderson Cancer Center and in 2000–2002 performed his oncology fellowship at University of North Carolina, Chapel Hill while focusing on immunotherapy. He founded CBOI in 2005 as a community-based clinic and the only independent cancer center on the East Coast that investigates Phase 1 clinical trial drugs. CBOI has opened more than 100 early phase clinical trials and serves as a regional referral hub for Phase 1 access. In addition, he founded a Human Applications Lab called BioCytics, whose purpose is to perform basic and translational research in immunological treatment of cancer.

R. Brent Dixon, PhD, is Laboratory Director of the Clinical and Human Applications Laboratory of Carolina BioOncology Institute, PLLC. He previously directed the South Carolina DHEC Public Health Laboratory in Columbia, SC. He has a PhD in analytical chemistry and a BS in chemical engineering from North Carolina State University. He has a master’s degree in clinical management and leadership from The George Washington University School of Medicine and Health Sciences. Dr. Dixon is a fellow of the American Association of Clinical Chemistry Academy, the Association of Clinical Scientists, and is board certified as a high-complexity clinical laboratory director by the American Association of Bioanalysts and the National Registry of Certified Chemists.

Jennifer Montague, PhD, is Director of Scientific Business Development for Carolina BioOncology Institute, PLLC and facilitates collaborative relationships with other cell therapy-focused biotech and pharmaceutical companies. She has also held positions in the fields of Medical Information and Clinical Research. Jennifer has a PhD in Biochemistry and Biophysics from the University of North Carolina at Chapel Hill, where she studied the process of apoptosis, or programmed cell death.

Steve Bradley is Facility and HAL Business Manager for Carolina BioOncology Institute, PLLC. He previously worked in various manufacturing roles, most recently as Plant Manager for Mohawk Industries largest production site in Thomasville, NC. Steve has performed multiple facility startups, has a BS in Chemical Engineering from North Carolina State University, and an MBA from the McColl School of Business at Queens University in Charlotte.

Read now